Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly

Expert Review of Vaccines

Volumn 18, Issue 6, 2019, Pages 663-670

  Lapi, Francesco ^a   Marconi, Ettore ^a   Simonetti, Monica ^a   Baldo, Vincenzo ^b   Rossi, Alessandro ^c   Sessa, Aurelio ^c   Cricelli, Claudio ^c  

^a Health Search   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Italian Society of General Practitioner and Primary Care (SIMG)   (Italy)

Author keywords

hospitalization; Influenza vaccines; myocardial infarction; pneumonia; primary care; stroke

Indexed keywords

INFLUENZA VACCINE; MF 59TIV; MIFAMURTIDE; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEPRESSION; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK REDUCTION; SEASONAL INFLUENZA; SECONDARY ANALYSIS; VERY ELDERLY; IMMUNOLOGY; SENSITIVITY AND SPECIFICITY;

ADJUVANTS, IMMUNOLOGIC; AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PNEUMONIA; SENSITIVITY AND SPECIFICITY;

EID: 85067078208     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2019.1622418     Document Type: Article

References (46)

1. Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013. Euro Surveill. 2018;23:17-00454.
2. Sellers SA, Hagan RS, Hayden FG, et al. The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11:372–393.
3. World Health Organization (WHO). Vaccines against influenza - WHO position paper. Wkly Epidemiol Rec [Internet]. 2012;461–76. [cited 2019 Jan 27]. Available from: https://www.who.int/immunization/position_papers/PP_influenza_november2012_summary.pdf
4. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama. 2003;289:179–186.
5. European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe–vaccination recommendations and coverage rates in the EU Member States for eight influenza seasons 2007-2008 to 2014-2015 [Internet] ECDC. 2017. [cited 2019 Jan 28]. Available from: https://ecdc.europa.eu/sites/portal/files/documents/influenza-vaccination-2007–2008-to-2014–2015.pdf
6. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018-19 influenza season. MMWR Recomm Rep. 2018;67:1–20.
7. Haq K, McElhaney JE., Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol. 2014;29:38–42.
8. Grubeck-Loebenstein B, Della Bella S, Iorio AM, et al. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res [Internet]. 2009;21:201–209; [cited 2019 Apr4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19571643
9. Weinberger B, Herndler-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46:1078–1084.
10. Domnich A, Arata L, Amicizia D, et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017;35:513–520.
11. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in Northern Italy. Am J Epidemiol. 2012;176:527–533.
12. Iob A, Brianti G, Zamparo E, et al. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect. 2005;133:687–693.
13. Van Buynder PG, Konrad S, Van Buynder JL, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013;31:6122–6128.
14. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001;19:2673–2680.
15. Orsi A, Ansaldi F, de Florentiis D, et al. Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines. Hum Vaccin Immunother. 2013;9:582–590.
16. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27:6959–6965.
17. Baldo V, Baldovin T, Pellegrini M, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol. 2010;2010:517198.
18. Public Health England (PHE). Guidance. Summary of data to support the choice of influenza vaccination for adults in primary care [Internet]. 2018. [cited 2019 Feb 5]. Available from: https://www.gov.uk/government/publications/flu-vaccination-supporting-data-for-adult-vaccines/summary-of-data-to-support-the-choice-of-influenza-vaccination-for-adults-in-primary-care
19. Italian Ministry of Health. Prevention and control of influenza: recommendations for the season 2018/19 [Internet]. 2018. [cited 2019 Feb5]. Available from: http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2018&codLeg=64381&parte=1&serie=null
20. Guglielmi V, Bellia A, Bianchini E, et al. Drug interactions in users of tablet vs oral liquid levothyroxine formulations: a real-world evidence study in primary care. Endocrine. 2018;59:585–592.
21. Cricelli C, Mazzaglia G, Samani F, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med. 2003;25:254–257.
22. Trifirò G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72:694–700.
23. Gasparini R, Bonanni P, Amicizia D, et al. Influenza epidemiology in Italy two years after the 2009-2010 pandemic: need to improve vaccination coverage. Hum Vaccin Immunother. 2013;9:561–567.
24. Instituto Superiore Di Sanita, Rome I. Influnet: Sorveglianza Epidemiologica. (In Italian) [Internet]; [cited 2019 Feb5]. Available from: http://old.iss.it/flue/
25. Rastogi S, Gross PA, Bonelli J, et al. Time to peak serum antibody response to influenza vaccine. Clin Diagn Lab Immunol. 1995;2:120–121.
26. Lu Y, Team A, Relative effectiveness of cell-cultured versus egg-based influenza vaccines [Internet]. 2018. [cited 2019 Feb 5]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-06/flu-03-Lu-508.pdf
27. Puig-Barberà J, Díez-Domingo J, Varea AB, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007;25:7313–7321.
28. Breslow NE. Statistics in epidemiology: the case-control study. J Am Stat Assoc. 1996;91:14–28.
29. Italian Medication Agency. Banca Dati Farmaci - AIFA [Internet]. [cited 2019 Feb5]. Available from: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/
30. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
31. Italian Medicines Agency Agenzia Italiana del Farmaco A. Nota 13 [Internet]. [cited 2018 Jun12]. Available from: http://www.agenziafarmaco.gov.it/content/nota-13
32. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–2381.
33. Saito N, Komori K, Suzuki M, et al. Negative impact of prior influenza vaccination on current influenza vaccination among people infected and not infected in prior season: a test-negative case-control study in Japan. Vaccine. 2017;35:687–693.
34. Morimoto N, Takeishi K. Change in the efficacy of influenza vaccination after repeated inoculation under antigenic mismatch: a systematic review and meta-analysis. Vaccine. 2018;36:949–957.
35. Valenciano M, Kissling E, Larrauri A, et al. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017. Influenza Other Respir Viruses. 2018;12:567–581.
36. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615–625.
37. Skowronski DM, De Serres G, Janjua NZ, et al. Re: “effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy”. Am J Epidemiol. 2013;177:593–594.
38. De Serres G. Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness. Vaccine. 2014;32:6596.
39. Ernster VL. Nested case-control studies. Prev Med (Baltim). 1994;23:587–590.
40. Centers for Disease Control and Prevention (CDC). Summary of the 2017-2018 influenza season [Internet]. [cited 2019 Apr4]. Available from: https://www.cdc.gov/flu/about/season/flu-season-2017-2018.htm
41. Panatto D, Signori A, Lai PL, et al. Heterogeneous estimates of influenza virus types A and B in the elderly: results of a meta-regression analysis. Influenza Other Respir Viruses. 2018;12:533–543.
42. Beyer WEP, Palache AM, Boulfich M, et al. Rationale for two influenza B lineages in seasonal vaccines: a meta-regression study on immunogenicity and controlled field trials. Vaccine. 2017;35:4167–4176.
43. Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2017–2018 [Internet] Gov. Canada. [cited 2018 Dec27]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2017-2018.html
44. Bonanni P, Boccalini S, Zanobini P, et al. The appropriateness of the use of influenza vaccines: recommendations from the latest seasons in Italy. Hum Vaccin Immunother. 2018;14:699–705.
45. Italian Ministry of Health. Coperture della vaccinazione antinfluenzale in Italia [Influenza vaccination coverage data] [Internet]. 2018; [cited 2019 Feb5]. Available from: http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area=influenza&menu=vuoto
46. Levi M, Bonanni P, Biffino M, et al. Influenza vaccination 2014-2015: results of a survey conducted among general practitioners in Italy. Hum Vaccin Immunother. 2018;14:1342–1350.